Swedish drugmaker SOBI receives $8bn bid from Advent and Aurora

Swedish drugmaker SOBI receives $8bn bid from Advent and Aurora

Swedish Orphan Biovitrum (SOBI) said on Thursday it had received a bid from U.S. private equity firm Advent International and Aurora Investment valuing the rare disease drugmaker at about $8bn. SOBI’s stock, already up 15% so far this year, rose 24.6% to 239 crowns...